Roth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12
Coya Therapeutics, Inc.
Coya Therapeutics, Inc. COYA | 0.00 |
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ:
COYA) with a Buy rating and announces Price Target of $12.
